The DOI matches its Crossref record; 72 of the 72 references it cites were found in a registry or an index.
GLP-1 Receptor Stimulation Reduces Amyloid-β Peptide Accumulation and Cytotoxicity in Cellular and Animal Models of Alzheimer's Disease
Open accessAbstract
Type 2 (T2) diabetes mellitus (DM) has been associated with an increased incidence of neurodegenerative disorders, including Alzheimer's disease (AD). Several pathological features are shared between diabetes and AD, including dysfunctional insulin signaling and a dysregulation of glucose metabolism. It has therefore been suggested that not only may the two conditions share specific molecular mechanisms but also that agents with proven efficacy in one may be useful against the other. Hence, the present study characterized the effects of a clinically approved long-acting analogue, exendin-4 (Ex-4), of the endogenous insulin releasing incretin, glucagon-like peptide-1 (GLP-1), on stress-induced toxicity in neuronal cultures and on amyloid-beta protein (Abeta) and tau levels in triple transgenic AD (3xTg-AD) mice with and without streptozocin (STZ)-induced diabetes. Ex-4 ameliorated the toxicity of Abeta and oxidative challenge in primary neuronal cultures and human SH-SY5Y cells in a concentration-dependent manner. When 11 to 12.5 month old female 3xTg AD mice were challenged with STZ or saline, and thereafter treated with a continuous subcutaneous infusion of Ex-4 or vehicle, Ex-4 ameliorated the diabetic effects of STZ in 3xTg-AD mice, elevating plasma insulin and lowering both plasma glucose and hemoglobin A1c (HbA1c) levels. Furthermore, brain levels of Abeta protein precursor and Abeta, which were elevated in STZ 3xTg-AD mice, were significantly reduced in Ex-4 treated mice. Brain tau levels were unaffected following STZ challenge, but showed a trend toward elevation that was absent following Ex-4 treatment. Together, these results suggest a potential value of Ex-4 in AD, particularly when associated with T2DM or glucose intolerance.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Wild, S., Roglic, G., Green, A., Sicree, R., & King, H. (2004) · Diabetes Care · doi:10.2337/diacare.27.5.1047 · Cited by 15,297
The Amyloid Hypothesis of Alzheimer’s Disease: Progress and Problems on the Road to Therapeutics
Hardy, J., & Selkoe, D. J. (2002) · Science · doi:10.1126/science.1072994 · Cited by 13,864
Global prevalence of dementia: a Delphi consensus study
Ferri, C. P., Prince, M., Brayne, C., Brodaty, H., Fratiglioni, L., Ganguli, M., Hall, K., Hasegawa, K., Hendrie, H., Huang, Y., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67889-0 · Cited by 5,332
Triple-Transgenic Model of Alzheimer’s Disease with Plaques and Tangles
Oddo, S., Caccamo, A., Shepherd, J. D., Murphy, M. P., Golde, T. E., Kayed, R., Metherate, R., Mattson, M. P., Akbari, Y., & LaFerla, F. M. (2003) · Neuron · doi:10.1016/s0896-6273(03)00434-3 · Cited by 4,126
Self-citationReducing Endogenous Tau Ameliorates Amyloid ß-Induced Deficits in an Alzheimer's Disease Mouse Model
Roberson, E. D., Scearce-Levie, K., Palop, J. J., Yan, F., Cheng, I. H., Wu, T., Gerstein, H., Yu, G.-Q., & Mucke, L. (2007) · Science · doi:10.1126/science.1141736 · Cited by 1,892
Steen, E., Terry, B. M., J. Rivera, E., Cannon, J. L., Neely, T. R., Tavares, R., Xu, X. J., Wands, J. R., & de la Monte, S. M. (2005) · Journal of Alzheimer's Disease · doi:10.3233/jad-2005-7107 · Cited by 1,703 · cited 1×
“Amongst numerous deficits in AD brain, insulin receptors are likewise reported desensitized, and this condition has been termed ‘type3 diabetes’ [43].”
Shibata, M., Yamada, S., Kumar, S. R., Calero, M., Bading, J., Frangione, B., Holtzman, D. M., Miller, C. A., Strickland, D. K., Ghiso, J., et al. (2000) · Journal of Clinical Investigation · doi:10.1172/jci10498 · Cited by 1,413
Diabetes mellitus and risk of Alzheimer disease and decline in cognitive function
Arvanitakis, Z., Wilson, R. S., Bienias, J. L., Evans, D. A., & Bennett, D. A. (2004) · Archives of Neurology · doi:10.1001/archneur.61.5.661 · Cited by 1,258 · cited 1×
“Mild to moderate impairments in cognitive function have been reported in both Type 1 (T1) and T2DM [40, 41], and epidemiological studies have linked T2DM and hyperinsulinemia with an increased risk of developing AD (as well as vascular dementia) in elderly people [3,4,6,9–12].”
Drucker, D. J., Buse, J. B., Taylor, K., Kendall, D. M., Trautmann, M., Zhuang, D., & Porter, L. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61206-4 · Cited by 1,070
Metabolic Regulation of Brain Aβ by Neprilysin
Iwata, N., Tsubuki, S., Takaki, Y., Shirotani, K., Lu, B., Gerard, N. P., Gerard, C., Hama, E., Lee, H.-J., & Saido, T. C. (2001) · Science · doi:10.1126/science.1059946 · Cited by 961
Chishti, M. A., Yang, D.-S., Janus, C., Phinney, A. L., Horne, P., Pearson, J., Strome, R., Zuker, N., Loukides, J., French, J., et al. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m100710200 · Cited by 955
Glucagon-like peptide-1 receptor is involved in learning and neuroprotection
During, M. J., Cao, L., Zuzga, D. S., Francis, J. S., Fitzsimons, H. L., Jiao, X., Bland, R. J., Klugmann, M., Banks, W. A., Drucker, D. J., et al. (2003) · Nature Medicine · doi:10.1038/nm919 · Cited by 851
Insulin-degrading Enzyme Regulates Extracellular Levels of Amyloid β-Protein by Degradation
Qiu, W. Q., Walsh, D. M., Ye, Z., Vekrellis, K., Zhang, J., Podlisny, M. B., Rosner, M. R., Safavi, A., Hersh, L. B., & Selkoe, D. J. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.49.32730 · Cited by 812
Oddo, S., Billings, L., Kesslak, J. P., Cribbs, D. H., & LaFerla, F. M. (2004) · Neuron · doi:10.1016/j.neuron.2004.07.003 · Cited by 780
Cognition and synaptic plasticity in diabetes mellitus
Gispen, W. H., & Biessels, G.-J. (2000) · Trends in Neurosciences · doi:10.1016/s0166-2236(00)01656-8 · Cited by 772
Gender differences in the incidence of AD and vascular dementia: The EURODEM Studies
Andersen, K., Launer, L. J., Dewey, M. E., Letenneur, L., Ott, A., Copeland, J. R. M., Dartigues, J.-F., Kragh–Sorensen, P., Baldereschi, M., Brayne, C., et al. (1999) · Neurology · doi:10.1212/wnl.53.9.1992 · Cited by 650
Incretin-based therapies for type 2 diabetes mellitus
Lovshin, J. A., & Drucker, D. J. (2009) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2009.48 · Cited by 649
ALZHEIMER'S DISEASE INTERNATIONAL
GRAHAM, N., & BRODATY, H. (1997) · International Journal of Geriatric Psychiatry · doi:10.1002/(sici)1099-1166(199707)12:7<691::aid-gps648>3.0.co;2-f · Cited by 634
Stranahan, A. M., Arumugam, T. V., Cutler, R. G., Lee, K., Egan, J. M., & Mattson, M. P. (2008) · Nature Neuroscience · doi:10.1038/nn2055 · Cited by 611
Self-citationGlucagon-like Peptide-1 Receptor Signaling Modulates β Cell Apoptosis
Li, Y., Hansotia, T., Yusta, B., Ris, F., Halban, P. A., & Drucker, D. J. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m209423200 · Cited by 589
Self-citationLi, Y., Perry, T., Kindy, M. S., Harvey, B. K., Tweedie, D., Holloway, H. W., Powers, K., Shen, H., Egan, J. M., Sambamurti, K., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0806720106 · Cited by 589
Self-citationThe relationship between impaired glucose tolerance, type 2 diabetes, and cognitive function
Awad, N., Gagnon, M., & Messier, C. (2004) · Journal of Clinical and Experimental Neuropsychology · doi:10.1080/13803390490514875 · Cited by 551
The Role of Metabolic Disorders in Alzheimer Disease and Vascular Dementia: Two Roads Converged
Craft, S. (2009) · Archives of Neurology · doi:10.1001/archneurol.2009.27 · Cited by 547
Reger, M. A., Watson, G. S., Green, P. S., Baker, L. D., Cholerton, B., Fishel, M. A., Plymate, S. R., Cherrier, M. M., Schellenberg, G. D., Frey II, W. H., et al. (2008) · Journal of Alzheimer's Disease · doi:10.3233/jad-2008-13309 · Cited by 521
Craft, S. (2007) · Current Alzheimer Research · doi:10.2174/156720507780362137 · Cited by 487 · cited 3×
“…high glucose is mediated to a significant degree via an increased productionof reactive oxygenand nitrogen species and subsequent oxidative stress [5,10– 12] that, like A β , can both directly inflict cellular damage and activate a number of cellular stress-sensitive pathways to induce cellular…”
Cukierman-Yaffe, T., Gerstein, H. C., Williamson, J. D., Lazar, R. M., Lovato, L., Miller, M. E., Coker, L. H., Murray, A., Sullivan, M. D., Marcovina, S. M., et al. (2009) · Diabetes Care · doi:10.2337/dc08-1153 · Cited by 452
Protection and Reversal of Excitotoxic Neuronal Damage by Glucagon-Like Peptide-1 and Exendin-4
Perry, T., Haughey, N. J., Mattson, M. P., Egan, J. M., & Greig, N. H. (2002) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.037481 · Cited by 380
Self-citationHu, J., Igarashi, A., Kamata, M., & Nakagawa, H. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m104068200 · Cited by 360
Entry of exendin-4 into brain is rapid but may be limited at high doses
Kastin, A. J., & Akerstrom, V (2003) · International Journal of Obesity · doi:10.1038/sj.ijo.0802206 · Cited by 355
Therapies for hyperglycaemia-induced diabetic complications: from animal models to clinical trials
Calcutt, N. A., Cooper, M. E., Kern, T. S., & Schmidt, A. M. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2476 · Cited by 352
Perry, T., Lahiri, D. K., Sambamurti, K., Chen, D., Mattson, M. P., Egan, J. M., & Greig, N. H. (2003) · Journal of Neuroscience Research · doi:10.1002/jnr.10611 · Cited by 347
Self-citationBertilsson, G., Patrone, C., Zachrisson, O., Andersson, A., Dannaeus, K., Heidrich, J., Kortesmaa, J., Mercer, A., Nielsen, E., Rönnholm, H., et al. (2008) · Journal of Neuroscience Research · doi:10.1002/jnr.21483 · Cited by 345
Oxidative Stress Signaling in Alzheimers Disease
Su, B., Wang, X., Nunomura, A., Moreira, P., Lee, H.-G., Perry, G., Smith, M., & Zhu, X. (2008) · Current Alzheimer Research · doi:10.2174/156720508786898451 · Cited by 344
Transport of Insulin Across the Blood-Brain Barrier: Saturability at Euglycemic Doses of Insulin
Banks, W. A., Jaspan, J. B., Huang, W., & Kastin, A. J. (1997) · Peptides · doi:10.1016/s0196-9781(97)00231-3 · Cited by 318
Mattson, M. P. (2009) · Experimental Gerontology · doi:10.1016/j.exger.2009.07.003 · Cited by 301
Self-citationPerry, T., Lahiri, D. K., Chen, D., Zhou, J., Shaw, K. T. Y., Egan, J. M., & Greig, N. H. (2002) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.300.3.958 · Cited by 300
Self-citationHarkavyi, A., Abuirmeileh, A., Lever, R., Kingsbury, A. E., Biggs, C. S., & Whitton, P. S. (2008) · Journal of Neuroinflammation · doi:10.1186/1742-2094-5-19 · Cited by 289
Jolivalt, C. G., Lee, C. A., Beiswenger, K. K., Smith, J. L., Orlov, M., Torrance, M. A., & Masliah, E. (2008) · Journal of Neuroscience Research · doi:10.1002/jnr.21787 · Cited by 287
Females exhibit more extensive amyloid, but not tau, pathology in an Alzheimer transgenic model
Hirata-Fukae, C., Li, H.-F., Hoe, H.-S., Gray, A. J., Minami, S. S., Hamada, K., Niikura, T., Hua, F., Tsukagoshi-Nagai, H., Horikoshi-Sakuraba, Y., et al. (2008) · Brain Research · doi:10.1016/j.brainres.2008.03.079 · Cited by 284
Self-citationAbbas, T., Faivre, E., & Hölscher, C. (2009) · Behavioural Brain Research · doi:10.1016/j.bbr.2009.06.035 · Cited by 282
Oxidative Stress in Diabetes and Alzheimer's Disease
Reddy, V. P., Zhu, X., Perry, G., & Smith, M. A. (2009) · Journal of Alzheimer's Disease · doi:10.3233/jad-2009-1013 · Cited by 280
Oxidative stress in vascular dementia and Alzheimer’s disease: a common pathology
Bennett, S., Grant, M. M., & Aldred, S. (2008) · Journal of Alzheimer's Disease · doi:10.3233/jad-2009-1041 · Cited by 254
Insulin Resistance and Alzheimers Disease: Molecular Links & Clinical Implications
Neumann, K., Rojo, L., Navarrete, L., Farias, G., Reyes, P., & Maccioni, R. (2008) · Current Alzheimer Research · doi:10.2174/156720508785908919 · Cited by 236 · cited 1×
“…both insulin and closely related insulin-like growth factor I (IGF-I) have been reported to both regulate and be regulated by A β and tau [44–46], and, in prelim-inary studies, intranasal insulin has been reported to augment verbal memory in adults with AD and MCI who were not APOE ε 4…”
Hamilton, A., & Hölscher, C. (2009) · NeuroReport · doi:10.1097/wnr.0b013e32832fbf14 · Cited by 227 · cited 2×
“Ex-4 has been reported to readily cross the bloodbrain barrier and enter the brain [20], where GLP-1R is expressed widely [21,22] and its activation results in multiple biological responses [21,23].”
Adiposity, Type 2 Diabetes, and Alzheimer's Disease
Luchsinger, J. A., & Gustafson, D. R. (2009) · Journal of Alzheimer's Disease · doi:10.3233/jad-2009-1022 · Cited by 211
Eckman, E. A., Adams, S. K., Troendle, F. J., Stodola, B. A., Kahn, M. A., Fauq, A. H., Xiao, H. D., Bernstein, K. E., & Eckman, C. B. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m605827200 · Cited by 196 · cited 1×
“…several pathways, including efflux via the low-density lipoprotein receptor-related protein 1 (LRP1) at the blood-brain barrier [59], and proteolytic enzyme degradation by neprilysin [60,61], insulin-degrading enzyme [62], endothelin-converting enzyme [61], and angiotensin converting enzyme [63].”
Greig, N. H., Holloway, H. W., De Ore, K. A., Jani, D., Wang, Y., Zhou, J., Garant, M. J., & Egan, J. M. (1999) · Diabetologia · doi:10.1007/s001250051111 · Cited by 189
Self-citationKamal, A., Biessels, G.-J., Urban, I. J. A., & Gispen, W. H. (1999) · Neuroscience · doi:10.1016/s0306-4522(98)00485-0 · Cited by 188
Advances in the Cellular and Molecular Biology of the Beta-Amyloid Protein in Alzheimer 's Disease
Sambamurti, K., Greig, N. H., & Lahiri, D. K. (2002) · NeuroMolecular Medicine · doi:10.1385/nmm:1:1:1 · Cited by 185
Self-citationPerry, T., Holloway, H. W., Weerasuriya, A., Mouton, P. R., Duffy, K., Mattison, J. A., & Greig, N. H. (2007) · Experimental Neurology · doi:10.1016/j.expneurol.2006.09.028 · Cited by 182
Self-citationMartin, B., Golden, E., Carlson, O. D., Pistell, P., Zhou, J., Kim, W., Frank, B. P., Thomas, S., Chadwick, W. A., Greig, N. H., et al. (2009) · Diabetes · doi:10.2337/db08-0799 · Cited by 181
Self-citationGLP-1 agonists facilitate hippocampal LTP and reverse the impairment of LTP induced by beta-amyloid
Gault, V. A., & Hölscher, C. (2008) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2008.03.025 · Cited by 168
Impairment of hippocampal neurogenesis in streptozotocin-treated diabetic rats
Zhang, W.-J., Tan, Y., Yue, J. T. Y., Vranić, M., & Wojtowicz, J. M. (2007) · Acta Neurologica Scandinavica · doi:10.1111/j.1600-0404.2007.00928.x · Cited by 163
Learning Decreases Aβ*56 and Tau Pathology and Ameliorates Behavioral Decline in 3xTg-AD Mice
Billings, L. M., Green, K. N., McGaugh, J. L., & LaFerla, F. M. (2007) · Journal of Neuroscience · doi:10.1523/jneurosci.4800-06.2007 · Cited by 161
Freude, S., Schilbach, K., & Schubert, M. (2009) · Current Alzheimer Research · doi:10.2174/156720509788486527 · Cited by 144
Mechanism of Tau-Induced Neurodegeneration in Alzheimer Disease and Related Tauopathies
Alonso, A. D. C., Li, B., Grundke, I., & Iqbal, K. (2008) · Current Alzheimer Research · doi:10.2174/156720508785132307 · Cited by 128
Perry, T., & Greig, N. (2005) · Current Alzheimer Research · doi:10.2174/1567205054367892 · Cited by 127
Self-citationMemantine lowers amyloid‐β peptide levels in neuronal cultures and in APP/PS1 transgenic mice
Alley, G. M., Bailey, J. A., Chen, D., Ray, B., Puli, L., Tanila, H., Banerjee, P., & Lahiri, D. K. (2009) · Journal of Neuroscience Research · doi:10.1002/jnr.22172 · Cited by 126
Self-citationGilman, C. P., Perry, T., Furukawa, K., Grieg, N. H., Egan, J. M., & Mattson, M. P. (2003) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2003.02073.x · Cited by 125
Self-citationThe glucagon-like peptides: a double-edged therapeutic sword?
Perry, T., & Greig, N. H. (2003) · Trends in Pharmacological Sciences · doi:10.1016/s0165-6147(03)00160-3 · Cited by 122
Self-citationHyperglycaemia as a determinant of cognitive decline in patients with type 1 diabetes
Wessels, A. M., Scheltens, P., Barkhof, F., & Heine, R. J. (2008) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2007.11.080 · Cited by 122
Common features between diabetes mellitus and Alzheimer’s disease
Götz, J., Ittner, L. M., & Lim, Y.-A. (2009) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-009-9070-1 · Cited by 117
Lahiri, D. K., Chen, D., Ge, Y., Bondy, S. C., & Sharman, E. H. (2004) · Journal of Pineal Research · doi:10.1111/j.1600-079x.2004.00121.x · Cited by 113
Self-citationA New Alzheimers Disease Interventive Strategy: GLP-1
Perry, T. R., & Greig, N. H. (2004) · Current Drug Targets · doi:10.2174/1389450043345245 · Cited by 110
Self-citationPEDERSEN, W., & FLYNN, E. (2004) · Neurobiology of Disease · doi:10.1016/j.nbd.2004.08.003 · Cited by 108 · cited 1×
“The mechanism(s) underpinning actions on A β PP and A β are likely multiple, as insulin and IRS-1 are key factors in many of the pathways involved in A β degradation [65,66], and are a focus of current studies.”
The AβCs of Aβ-cleaving Proteases
Leissring, M. A. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.r800022200 · Cited by 94
Genetic determinants and molecular pathways in the pathogenesis of Type 2 diabetes
Jin, W., & Patti, M. (2008) · Clinical Science · doi:10.1042/cs20080090 · Cited by 92
Toro, P., Schönknecht, P., & Schröder, J. (2009) · Journal of Alzheimer s Disease · doi:10.3233/jad-2009-0981 · Cited by 71 · cited 1×
“Indeed, several studies have reported that diabetic patients have a 2-to 5-fold elevated risk for AD, as compared with non-diabetic subjects [8– 12].”
Increased amyloid β-peptide (1–40) level in brain of streptozotocin-induced diabetic rats
Liu, Y., Liu, H., Yang, J., Liu, X., Lü, S., Wen, T., Xie, L. Y., & Wang, G. (2008) · Neuroscience · doi:10.1016/j.neuroscience.2008.03.019 · Cited by 64
A Partial Failure of Membrane Protein Turnover May Cause Alzheimers Disease: A New Hypothesis
Sambamurti, K., Suram, A., Venugopal, C., Prakasam, A., Zhou, Y., Lahiri, D. K., & Greig, N. H. (2006) · Current Alzheimer Research · doi:10.2174/156720506775697142 · Cited by 62
Self-citationJones, A., Kulozik, P., Ostertag, A., & Herzig, S. (2009) · Journal of Alzheimer s Disease · doi:10.3233/jad-2009-0973 · Cited by 51
Role of Insulin Metabolism Disturbances in the Development of Alzheimer Disease: Mini Review
Sabayan, B., Foroughinia, F., Mowla, A., & Borhani‐Haghighi, A. (2008) · American Journal of Alzheimer s Disease & Other Dementias® · doi:10.1177/1533317507312623 · Cited by 29
Cited by
Talbot, K., Wang, H.-Y., Kazi, H., Han, L.-Y., Bakshi, K. P., Stucky, A., Fuino, R. L., Kawaguchi, K. R., Samoyedny, A. J., Wilson, R. S., et al. (2012) · Journal of Clinical Investigation · doi:10.1172/jci59903 · Cited by 1,871
Hallmarks of Brain Aging: Adaptive and Pathological Modification by Metabolic States
Mattson, M. P., & Arumugam, T. V. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2018.05.011 · Cited by 1,242
Self-citationKapogiannis, D., & Mattson, M. P. (2011) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70277-5 · Cited by 594
Self-citationBDNF mediates adaptive brain and body responses to energetic challenges
Marosi, K., & Mattson, M. P. (2014) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2013.10.006 · Cited by 568
Self-citationHunter, K., & Hölscher, C. (2012) · BMC Neuroscience · doi:10.1186/1471-2202-13-33 · Cited by 504
Metadata
- Authors
- Li, Y., Duffy, K. B., Ottinger, M. A., Ray, B., Bailey, J. A., Holloway, H. W., Tweedie, D., Perry, T., Mattson, M. P., Kapogiannis, D., Sambamurti, K., Lahiri, D. K., & Greig, N. H.
- Venue
- Journal of Alzheimer's Disease
- Publisher
- SAGE Publications
- Published
- 2010-03-11
- Volume
- 19
- Issue
- 4
- Pages
- 1205-1219
- ISSN
- 1387-2877 (ISSN-L)
- 1875-8908
- OpenAlex
- W2152355721
- Cited by
- 321
- References
- 72
- FWCI
- 14.08
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.